Revolution Medicines, Inc.
RVMD
$99.00
$4.144.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 782.32M | 675.48M | 564.72M | 558.37M | 470.64M |
| Gross Profit | -782.32M | -675.48M | -564.72M | -558.37M | -470.64M |
| SG&A Expenses | 195.04M | 156.57M | 127.77M | 108.90M | 96.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.18B | 1.04B | 897.50M | 789.43M | 689.52M |
| Operating Income | -1.18B | -1.04B | -897.50M | -789.43M | -689.52M |
| Income Before Tax | -1.13B | -961.73M | -812.81M | -698.26M | -600.85M |
| Income Tax Expenses | -- | -753.00K | -753.00K | -753.00K | -753.00K |
| Earnings from Continuing Operations | -1.13K | -960.98 | -812.06 | -697.51 | -600.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.13B | -960.98M | -812.06M | -697.51M | -600.09M |
| EBIT | -1.18B | -1.04B | -897.50M | -789.43M | -689.52M |
| EBITDA | -1.17B | -1.03B | -890.70M | -782.75M | -683.00M |
| EPS Basic | -5.92 | -5.18 | -4.50 | -4.00 | -3.57 |
| Normalized Basic EPS | -3.70 | -3.24 | -2.82 | -2.50 | -2.23 |
| EPS Diluted | -5.92 | -5.18 | -4.50 | -4.00 | -3.57 |
| Normalized Diluted EPS | -3.70 | -3.24 | -2.82 | -2.50 | -2.23 |
| Average Basic Shares Outstanding | 762.63M | 739.72M | 717.33M | 693.89M | 670.47M |
| Average Diluted Shares Outstanding | 762.63M | 739.72M | 717.33M | 693.89M | 670.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |